Search Results - ici

3 Results Sort By:
Personalized Tumor Vaccine and Use Thereof for Cancer Immunotherapy
Abstract: Immune checkpoint inhibitors (ICIs) vastly improved the outcome of various advanced cancers; however, many are less likely to respond to single-agent ICI. Tumors with low T-cell infiltration are "immunologically cold" and less likely to respond to single-agent ICI therapy. This diminished response is presumably due to the lack of neoantigens...
Published: 4/8/2024   |   Inventor(s): Zhengping (Ping) Zhuang, Karel Pacak, Jan Zenka, Rogelio Medina, Herui Wang, Sze Chun (Winson) Ho
Keywords(s): Anti-CD40-Monoclonal Antibody, CANCER, ICI, Immune Checkpoint Inhibitors, Mannan-BAM, Oncology, TLR, Toll-like receptor, Tumor Vaccine, Zhuang
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics
Method for HLA LOH Detection in Liquid Biopsies
Abstract: Human leukocyte antigen (HLA) LOH (LOH) is a known resistance mechanism by which cancers evade T cell receptor-(TCR-)based immunotherapies. This class of therapies includes immune checkpoint inhibition (ICI, e.g., Pembrolizumab), engineered TCR (T cell receptor)-T cell adoptive transfer, tumor infiltrating lymphocytes (TIL), T-cell engagers,...
Published: 12/17/2024   |   Inventor(s): Andrew Sinkoe, James Gulley, Cem Sievers
Keywords(s): Companion Diagnostic, Gulley, HLA, Human Leukocyte Antigen, ICI, Immune Checkpoint Inhibition, Immunotherapy, LOH, Loss of Heterozygosity, Sinkoe, T cell therapy
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Diagnostics
Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors
Abstract: Programed Death-Ligand 1 (PD-L1, also known as B7-H1 or CD274) is a cell surface protein that binds to Programmed Cell Death Protein 1 (PD-1, also known as CD279). An imbalance in PD-1/PD-L1 activity contributes to cancer immune escape.  PD-1 is expressed on the surface of antigen-stimulated T cells. The interaction between PD-L1 and PD-1...
Published: 4/8/2024   |   Inventor(s): Mitchell Ho, Glenn Merlino, Dan Li, Hejiao English, Chi-Ping Day
Keywords(s): adoptive cell therapy, Chimeric Antigen Receptor T Cells, HO, ICI, Immune Checkpoint Inhibitor, Immunotherapy, NANOBODY, PD-L1, phage display, Programed Death-Ligand, Single Domain Antibody
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology